https://www.selleckchem.com/mTOR.html
66-8.99) were independent risk factors for OS, whereas PVIS plus TACE treatment (HR 0.32; 95% CI 0.18-0.56) was related to better prognosis. None of the patients in the two groups had grade 3-4 complications. In conclusion, this retrospective study shows that PVIS plus TACE provides a significantly better survival outcome than RT plus TACE for HCC patients with PVTT. In conclusion, this retrospective study shows that PVIS plus TACE provides a significantly better survival outcome than RT plus TACE for HCC patients with PVTT. To assess the safety an
Like
Comment
Share
